Berberine for Anti-Inflammatory

Research suggests that berberine exerts anti-inflammatory effects through multiple well-characterized molecular mechanisms, including suppression of NF-κB and NLRP3 signaling pathways, reduction of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, and direct binding to regulatory proteins such as EIF2AK2, with studies also identifying the p300/p65 acetylation axis and the MCP1/CCR2 recruitment pathway as additional targets. The available evidence comes predominantly from laboratory cell studies and animal models, with a smaller number of human clinical trials focused mainly on cardiometabolic outcomes rather than inflammation as a primary endpoint, and several review articles synthesizing findings across a decade of preclinical research. Studies indicate that berberine's notably poor oral bioavailability is a consistent and acknowledged limitation across the literature, though researchers have noted that its metabolites — including columbamine and berberrubine — appear to share similar anti-inflammatory properties and may contribute meaningfully to the compound's overall effects in the body. Overall, the body of evidence is directionally consistent in supporting berberine's anti-inflammatory potential, but the relative scarcity of large, well-controlled human trials means that translating these findings to clinical recommendations remains an open question.